Tanaka Hiroki, Matsusaki Shimpei
Department of Gastroenterology, Suzuka General Hospital, Suzuka 513-8630, Japan.
Diagnostics (Basel). 2022 Mar 19;12(3):753. doi: 10.3390/diagnostics12030753.
Endoscopic-ultrasonography-guided tissue acquisition (EUS-TA) has been widely performed for the definitive diagnosis of solid pancreatic lesions (SPLs). As the puncture needles, puncture techniques, and sample processing methods have improved, EUS-TA has shown higher diagnostic yields and safety. Recently, several therapeutic target genomic biomarkers have been clarified in pancreatic ductal carcinoma (PDAC). Although only a small proportion of patients with PDAC can benefit from precision medicine based on gene mutations at present, precision medicine will also be further developed for SPLs as more therapeutic target genomic biomarkers are identified. Advances in next-generation sequencing (NGS) techniques enable the examination of multiple genetic mutations in limited tissue samples. EUS-TA is also useful for NGS and will play a more important role in determining treatment strategies. In this review, we describe the utility of EUS-TA for SPLs.
内镜超声引导下组织获取术（EUS-TA）已广泛应用于实性胰腺病变（SPL）的明确诊断。随着穿刺针、穿刺技术和样本处理方法的改进，EUS-TA已显示出更高的诊断率和安全性。最近，胰腺导管腺癌（PDAC）中的几种治疗靶点基因组生物标志物已得到明确。尽管目前只有一小部分PDAC患者能从基于基因突变的精准医学中获益，但随着更多治疗靶点基因组生物标志物的发现，SPL的精准医学也将进一步发展。下一代测序（NGS）技术的进步使得在有限的组织样本中检测多种基因突变成为可能。EUS-TA对NGS也很有用，并且将在确定治疗策略中发挥更重要的作用。在这篇综述中，我们描述了EUS-TA对SPL的实用性。
